Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
July 2016
in “
Current pharmaceutical design
”
New to Metformin? There is a guide in the encyclopedia. Read the guide → Studysummary This review summarizes hair growth aspects, treatment options, and management strategies for hirsutism in women with polycystic ovary syndrome, without presenting new clinical findings.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study reviewed the pathophysiology and management of hirsutism in women with polycystic ovary syndrome (PCOS), noting that 70-80% of women with PCOS experience hirsutism compared to 4-11% in the general population. Hirsutism in PCOS was linked to ovarian-derived androgen excess and individual sensitivity to androgens. Treatment options included combined oral contraceptives (OCPs) to suppress androgen excess, with metformin and lifestyle changes as alternatives for those with contraindications to OCPs. The severity of hirsutism, assessed by the modified Ferriman-Gallwey score, and the distress it caused to patients guided treatment choices, which needed to be maintained for 6-12 months. Mild cases were treated with non-pharmacological methods and OCPs, while moderate to severe cases required antiandrogens and OCPs or a safe contraceptive method if OCPs were not suitable. Individualized management considering metabolic comorbidities and menstrual disturbances was emphasized for effective treatment.
